Latest & greatest articles for hydroxychloroquine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydroxychloroquine

1. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. (Full text)

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine (...) and 3155 to receive usual care. The primary outcome was 28-day mortality.The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients

2020 NEJM PubMed abstract

2. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? (Full text)

Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your (...) practice points on the use of chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of coronavirus disease 2019 (COVID-19) ( , ) from the living status. This decision was made in light of recent information on the topic. Three large, in-progress randomized controlled trials (RCTs) with strong study designs ceased enrollment for the hydroxychloroquine-only versus control comparison early due to lack of efficacy in preliminary analyses

2020 American College of Physicians PubMed abstract

3. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis (Full text)

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) . 2020 Aug 26;S1198-743X(20)30505-X. doi: 10.1016/j.cmi.2020.08.022. Online ahead of print. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis , , , , , Affiliations Expand Affiliations 1 CESP (Centre for Research in Epidemiology and Population Health), Faculté de Médecine-Université Paris-Sud, Faculté de Médecine-UVSQ, INSERM, Université Paris Saclay, Villejuif, France; Gustave Roussy

2020 EvidenceUpdates PubMed abstract

4. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis (Full text)

Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from (...) : Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Med Res Actions . 2020 Aug;12(8):483-491. doi: 10.14740/jocmr4233. Epub 2020 Jul 4. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review

2020 EvidenceUpdates PubMed abstract

5. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial (Full text)

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial CDEI - Hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial — CDEI Open Menu Close Menu Open Menu Close Menu Apr 21 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (...) (medRxiv). Citation: Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., ... & Zhang, Z. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. DOI: Full PICO and Limitations in text: Population: 62 adult (age ≥ 18), hospitalized patients with confirmed RT-PCR of SARS-CoV-2, chest CT with pneumonia, and mild illness (i.e. SaO2/SPO2 ratio > 93% or PaO2/FIO2 ratio > 300 mmHg on room air). Intervention: 31 patients received

2020 Covid-19 Drug Evidence Initiative PubMed abstract

6. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study (Full text)

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study CDEI - Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Jun 26 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should (...) not be reported in news media as established information (medRxiv). Citation: Chen, L. , Zhang, Z., Fu, J., Feng, Z., Zhang, S., ... Yin, Z. (2020). Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. medRxiv. DOI: Full PICO and Limitations in text: Population: 48 patients aged 18 to 75 years with moderate COVID-19, diagnosed by positive RT-PCR or with CT scan of the chest for lung changes characteristic of COVID-19

2020 Covid-19 Drug Evidence Initiative PubMed abstract

7. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial

Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial CDEI - Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial — CDEI Open Menu Close Menu Open Menu Close Menu Jul 18 Written By Citation: Skipper CP , Pastick KA, Engen NW, et al. (2020). Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial. Ann Intern Med. DOI: Full PICO and Limitations in text: Population: 491 nonhospitalized adults (≥18 years (...) ) with ≤4 days of symptoms and either confirmed SARS-CoV-2 infection or compatible symptoms after high-risk exposure to a person with confirmed COVID-19 within the past 14 days. Interventions and Comparator Intervention: 244 patients were randomized to receive hydroxychloroquine 800 mg PO once, then 600 mg PO 6 to 8 hours later, then 600 mg PO once daily for 4 more days (5 days in total). Comparator: 247 patients were randomized to receive placebo (folic acid 400 mcg at US sites, lactose at Canadian

2020 Covid-19 Drug Evidence Initiative

8. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study (Full text)

Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study CDEI - Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study — CDEI Open Menu Close Menu Open Menu Close Menu Aug 31 Written By Citation: Abd-Elsalam, S. , Esmail, E. S., Khalaf, M., Abdo, E. F., Medhat, M. A., Abd El Ghafar, M. S., ... & Alboraie, M. (2020). Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. The American (...) Journal of Tropical Medicine and Hygiene , tpmd200873. DOI: Full PICO and Limitations in text: Population: 194 hospitalized patients with suspected or confirmed COVID-19 infection. Intervention and Comparator Intervention: 97 patients were randomized to receive standard of care plus hydroxychloroquine 400mg twice daily on day 1, followed by 200mg twice daily for 15 days. Comparator: 97 patients were randomized to receive standard of care for 15 days. Outcomes: Primary outcomes: (1) Recovery within 28

2020 Covid-19 Drug Evidence Initiative PubMed abstract

9. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials (Full text)

Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) . Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials , , , , , , , Affiliations Expand Affiliations 1 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 2 Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. 3 Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.xiaoyu@zs-hospital.sh.cn. 4 Department of Pharmacy, Zhongshan

2020 EvidenceUpdates PubMed abstract

10. Covid-19: More about chloroquine and hydroxychloroquine

Covid-19: More about chloroquine and hydroxychloroquine More about chloroquine and hydroxychloroquine - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website More about chloroquine and hydroxychloroquine May 30, 2020 Jeffrey K Aronson, Robin E Ferner* On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University (...) of Oxford *University of Birmingham Correspondence to VERDICT The hypothesis that the 4-aminoquinolines chloroquine and hydroxychloroquine may be beneficial in the treatment of COVID-19 is a weak one, based on poor mechanistic reasoning and inconsistent results of studies in vitro, in laboratory animals, and in humans. It is likely that even if chloroquine and hydroxychloroquine are effective in COVID-19, the beneficial effects will be small. The risks of adverse reactions to these drugs may

2020 Oxford COVID-19 Evidence Service

11. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 (Full text)

Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Crit Care Actions . 2020 Jul 11;59:176-190. doi: 10.1016/j.jcrc.2020.06.019. Online ahead of print. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 , , , , , Affiliations

2020 EvidenceUpdates PubMed abstract

12. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review (Full text)

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review , , , , Affiliations Expand Affiliations 1 NYU Langone Health, NYU School of Medicine, New York, New York. Electronic address: Lior.Jankelson@nyulangone.org. 2 Dalhousie University, College of Pharmacy, Halifax, Nova Scotia, Canada. Electronic address: Giorgio.Karam@dal.ca. 3 Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands; Spaarne Gasthuis, Haarlem

2020 EvidenceUpdates PubMed abstract

13. Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease

Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease Prescrire IN ENGLISH - Spotlight ''Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease'', 24 July 2020 {1} {1} {1} | | > > > Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease NEWS UPDATE The detailed results of four comparative trials of hydroxychloroquine in patients with covid-19 were released in late July 2020: two trials in patients hospitalised for covid-19, and two others in patients who were not hospitalised and had milder forms of the disease. As of June 2020, hydroxychloroquine (Plaquenil°) had

2020 Prescrire

14. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. (Full text)

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute (...) of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified

2020 NEJM PubMed abstract

15. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. (Full text)

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients.Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668).Internet-based trial across the United States and Canada (40 states and 3 provinces).Symptomatic (...) , nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset.Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures: Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days.Of 491 patients randomly assigned to a group, 423 contributed

2020 Annals of Internal Medicine PubMed abstract

16. COVID-19: Treatment with Hydroxychloroquine (HCQ)

COVID-19: Treatment with Hydroxychloroquine (HCQ) COVID-19: TREATMENT WITH HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated June 26, 2020. All links rechecked June 26 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice guideline (...) , but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine safe and effective for treatment of COVID-19 disease? Use of hydroxychloroquine for prevention of COVID-19 disease is outside the scope of this report. Summary of major recommendations • The FDA has withdrawn Emergency Use Authorization for hydroxychloroquine in COVID-19 disease, but clinical trials remain in progress. • Systematic reviews of clinical evidence show

2020 Centre for Evidence-Based Practice, Penn Medicine

17. COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ)

COVID-19: Prophylactic Use of Hydroxychloroquine (HCQ) COVID-19: PROPHYLACTIC USE OF HYDROXYCHLOROQUINE (HCQ) A Rapid Guidance Summary from the Penn Medicine Center for Evidence-based Practice Last updated July 1, 2020. All links rechecked June 30 unless otherwise noted. This Rapid Guidance Summary is a description of existing guidance and evidence reviews from a variety of sources that was in effect at the time of publication. It should not be used or interpreted as a clinical practice (...) guideline, but instead can be used in development of local recommendations and policies. Key questions answered in this summary • Is hydroxychloroquine effective for prevention of clinical disease in patients who have been exposed to SARS-CoV-2? Use of hydroxychloroquine for treatment of confirmed COVID-19 disease is outside the scope of this report. Summary of major recommendations • Use of hydroxychloroquine or chloroquine for prevention of COVID-19 disease is not recommended outside of approved

2020 Centre for Evidence-Based Practice, Penn Medicine

18. Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Full text)

Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new (...) , Worcester, Massachusetts (G.M.A.) , Portland Veterans Affairs Medical Center, Portland, Oregon (A.J.O.) , University of Pennsylvania, Philadelphia, Pennsylvania (M.A.F.) , University of Illinois College of Medicine, Urbana, Illinois (J.A.J.) , Oregon Health & Science University, Portland, Oregon (L.L.H.) , In this letter, we update the American College of Physicians' previous practice points about chloroquine or hydroxychloroquine alone or in combination with azithromycin for prophylaxis or treatment

2020 American College of Physicians PubMed abstract

19. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review (Full text)

Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Neuroimmune Pharmacol Actions . 2020 Jun 9;1-9. doi: 10.1007/s11481-020-09930-x. Online ahead of print. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review , , , , Affiliations Expand Affiliations 1 Department of Pharmacology, All India Institute

2020 EvidenceUpdates PubMed abstract

20. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. (Full text)

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.We examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation (...) to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.Of 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376

2020 NEJM PubMed abstract